MGTX
Meiragtx Holdings Plc
NASDAQ · Biotechnology
$7.43
+0.23 (+3.19%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 38.36M | 39.99M | 317.19M | 298.22M | 353.14M |
| Net Income | -170,375,063 | -159,843,173 | -41,054,821 | -30,982,952 | -42,442,765 |
| EPS | — | — | — | — | — |
| Profit Margin | -444.1% | -421.9% | -12.9% | -10.4% | -12.0% |
| Rev Growth | -4.1% | -4.1% | +21.7% | -0.7% | -1.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 155.23M | 155.23M | 224.81M | 274.26M | 257.56M |
| Total Equity | 143.80M | 143.80M | 345.77M | 356.05M | 341.85M |
| D/E Ratio | 1.08 | 1.08 | 0.65 | 0.77 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -156,417,943 | -154,901,538 | -45,049,439 | -39,492,333 | -49,405,433 |
| Free Cash Flow | — | — | -29,515,122 | -35,501,473 | -31,424,329 |